Published in Antimicrob Agents Chemother on June 01, 1999
Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother (2001) 5.23
Antibiotic susceptibility profiles of Escherichia coli strains lacking multidrug efflux pump genes. Antimicrob Agents Chemother (2001) 3.87
CmeABC functions as a multidrug efflux system in Campylobacter jejuni. Antimicrob Agents Chemother (2002) 3.31
Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria. Antimicrob Agents Chemother (2000) 3.22
Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability. Antimicrob Agents Chemother (1999) 2.74
Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance. J Bacteriol (2000) 2.41
Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump. Antimicrob Agents Chemother (2000) 2.40
The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin Microbiol Rev (2015) 1.81
The MexJK efflux pump of Pseudomonas aeruginosa requires OprM for antibiotic efflux but not for efflux of triclosan. J Bacteriol (2002) 1.76
Genetic and phenotypic variations of a resistant Pseudomonas aeruginosa epidemic clone. Antimicrob Agents Chemother (2003) 1.48
Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2005) 1.27
MexXY-OprM efflux pump is required for antagonism of aminoglycosides by divalent cations in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2001) 1.19
Two efflux systems expressed simultaneously in multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother (2000) 1.18
Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. Antimicrob Agents Chemother (2008) 1.15
Recent advances toward a molecular mechanism of efflux pump inhibition. Front Microbiol (2015) 1.08
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. Antimicrob Agents Chemother (2007) 1.06
Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli. Antimicrob Agents Chemother (2012) 1.06
The intrinsic resistome of bacterial pathogens. Front Microbiol (2013) 1.05
In vivo increase in resistance to ciprofloxacin in Escherichia coli associated with deletion of the C-terminal part of MarR. Antimicrob Agents Chemother (2000) 1.01
In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. Antimicrob Agents Chemother (2009) 0.96
Characterization of a novel pyranopyridine inhibitor of the AcrAB efflux pump of Escherichia coli. Antimicrob Agents Chemother (2013) 0.95
Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2008) 0.95
Interaction of antibacterial compounds with RND efflux pumps in Pseudomonas aeruginosa. Front Microbiol (2015) 0.94
Pharmacodynamics of levofloxacin against Pseudomonas aeruginosa with reduced susceptibility due to different efflux pumps: do elevated MICs always predict reduced in vivo efficacy? Antimicrob Agents Chemother (2006) 0.93
Metabolic compensation of fitness costs associated with overexpression of the multidrug efflux pump MexEF-OprN in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2014) 0.92
Erythromycin resistance by L4/L22 mutations and resistance masking by drug efflux pump deficiency. EMBO J (2009) 0.89
Quantitative contributions of target alteration and decreased drug accumulation to Pseudomonas aeruginosa fluoroquinolone resistance. Antimicrob Agents Chemother (2012) 0.87
Drug efflux pump deficiency and drug target resistance masking in growing bacteria. Proc Natl Acad Sci U S A (2009) 0.86
Reduced susceptibility of Haemophilus influenzae to the peptide deformylase inhibitor LBM415 can result from target protein overexpression due to amplified chromosomal def gene copy number. Antimicrob Agents Chemother (2007) 0.85
High-level pacidamycin resistance in Pseudomonas aeruginosa is mediated by an opp oligopeptide permease encoded by the opp-fabI operon. Antimicrob Agents Chemother (2013) 0.84
Structure-activity relationships of a novel pyranopyridine series of Gram-negative bacterial efflux pump inhibitors. Bioorg Med Chem (2015) 0.83
Mechanism of resistance to an antitubercular 2-thiopyridine derivative that is also active against Burkholderia cenocepacia. Antimicrob Agents Chemother (2014) 0.82
Efflux-mediated fluoroquinolone resistance in the multidrug-resistant Pseudomonas aeruginosa clinical isolate PA7: identification of a novel MexS variant involved in upregulation of the mexEF-oprN multidrug efflux operon. Front Microbiol (2015) 0.82
The relative contribution of efflux and target gene mutations to fluoroquinolone resistance in recent clinical isolates of Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis (2010) 0.81
Selection of cross-resistance following exposure of Pseudomonas aeruginosa clinical isolates to ciprofloxacin or cefepime. Antimicrob Agents Chemother (2005) 0.80
Functional consequences of substitution mutations in MepR, a repressor of the Staphylococcus aureus MepA multidrug efflux pump gene. J Bacteriol (2013) 0.80
Permeability Barrier of Gram-Negative Cell Envelopes and Approaches To Bypass It. ACS Infect Dis (2016) 0.80
Bacterial Multidrug Efflux Pumps: Much More Than Antibiotic Resistance Determinants. Microorganisms (2016) 0.79
Non-equivalent roles of two periplasmic subunits in the function and assembly of triclosan pump TriABC from Pseudomonas aeruginosa. Mol Microbiol (2015) 0.78
Expression of the MexXY-OprM efflux system in Pseudomonas aeruginosa with discordant cefepime/ceftazidime susceptibility profiles. Infect Drug Resist (2008) 0.78
Reverse engineering antibiotic sensitivity in a multidrug-resistant Pseudomonas aeruginosa isolate. Antimicrob Agents Chemother (2006) 0.77
A Transporter Interactome Is Essential for the Acquisition of Antimicrobial Resistance to Antibiotics. PLoS One (2016) 0.75
Ligand Promiscuity between the Efflux Pumps Human P-Glycoprotein and S. aureus NorA. ACS Med Chem Lett (2012) 0.75
Antibacterial Properties of Alkaloid Extracts from Callistemon citrinus and Vernonia adoensis against Staphylococcus aureus and Pseudomonas aeruginosa. Int J Med Chem (2016) 0.75
Focus on the Outer Membrane Factor OprM, the Forgotten Player from Efflux Pumps Assemblies. Antibiotics (Basel) (2015) 0.75
Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother (1990) 11.71
Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science (1994) 11.18
Interposon mutagenesis of soil and water bacteria: a family of DNA fragments designed for in vitro insertional mutagenesis of gram-negative bacteria. Gene (1987) 11.03
Multidrug efflux pumps of gram-negative bacteria. J Bacteriol (1996) 9.86
Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon. J Bacteriol (1993) 8.95
Proton-dependent multidrug efflux systems. Microbiol Rev (1996) 8.81
Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol Microbiol (1997) 5.91
Resistance of Pseudomonas aeruginosa PAO to nalidixic acid and low levels of beta-lactam antibiotics: mapping of chromosomal genes. Antimicrob Agents Chemother (1982) 5.67
Multidrug resistance pumps in bacteria: variations on a theme. Trends Biochem Sci (1994) 5.21
Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa. Mol Microbiol (1996) 5.20
An improved system for gene replacement and xylE fusion analysis in Pseudomonas aeruginosa. Gene (1995) 5.18
Mutations producing resistance to norfloxacin in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1987) 4.96
Allelic exchange in Pseudomonas aeruginosa using novel ColE1-type vectors and a family of cassettes containing a portable oriT and the counter-selectable Bacillus subtilis sacB marker. Mol Microbiol (1992) 4.85
Active efflux mechanisms for antimicrobial resistance. Antimicrob Agents Chemother (1992) 4.82
Cross-resistance to meropenem, cephems, and quinolones in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1992) 4.74
Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob Agents Chemother (1996) 4.15
Outer membrane proteins responsible for multiple drug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1995) 3.98
Antibiotic resistance caused by gram-negative multidrug efflux pumps. Clin Infect Dis (1998) 3.85
Cloning and sequence analysis of an EnvCD homologue in Pseudomonas aeruginosa: regulation by iron and possible involvement in the secretion of the siderophore pyoverdine. Mol Microbiol (1993) 3.75
A novel transducing phage. Its role in recognition of a possible new host-controlled modification system in Pseudomonas aeruginosa. Mol Gen Genet (1972) 3.20
Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter. Antimicrob Agents Chemother (1993) 3.10
Mechanisms of resistance to beta-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993. J Med Microbiol (1995) 2.59
Inner membrane efflux components are responsible for beta-lactam specificity of multidrug efflux pumps in Pseudomonas aeruginosa. J Bacteriol (1997) 2.54
Cloning and nucleotide sequence of Pseudomonas aeruginosa DNA gyrase gyrA gene from strain PAO1 and quinolone-resistant clinical isolates. Antimicrob Agents Chemother (1994) 2.47
Characterization of the MexC-MexD-OprJ multidrug efflux system in DeltamexA-mexB-oprM mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1998) 2.29
Isolation of OprM-deficient mutants of Pseudomonas aeruginosa by transposon insertion mutagenesis: evidence of involvement in multiple antibiotic resistance. FEMS Microbiol Lett (1994) 2.07
Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1997) 2.06
Inhibition of the multidrug transporter NorA prevents emergence of norfloxacin resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1996) 1.83
nfxC-type quinolone resistance in a clinical isolate of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1995) 1.73
Occurrence of the nfxB type mutation in clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1992) 1.69
The role of mex-gene products in antibiotic extrusion in Pseudomonas aeruginosa. Biochem Biophys Res Commun (1997) 1.69
Mechanisms of resistance to fluoroquinolones: state-of-the-art 1992-1994. Drugs (1995) 1.60
Mechanisms of high-level resistance to quinolones in urinary tract isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1994) 1.60
Mutations in the gyrA and parC genes in fluoroquinolone-resistant clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1997) 1.44
Quinolone mode of action. Drugs (1995) 1.44
A Toll-like receptor recognizes bacterial DNA. Nature (2000) 26.34
Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity (1999) 17.40
Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ. Cell (1996) 6.87
Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol (2000) 6.61
Primary structure and expression from complementary DNA of skeletal muscle ryanodine receptor. Nature (1989) 6.07
Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell (1990) 5.73
Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol (2001) 5.27
Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother (2001) 5.23
Campylobacter pyloridis and gastritis: association with intercellular spaces and adaptation to an environment of mucus as important factors in colonization of the gastric epithelium. J Infect Dis (1986) 4.89
Enumeration of the oxygen sensitive bacteria usually present in the intestine of healthy mice. Nature (1968) 4.70
Cloning of the beta subunit of the leukocyte adhesion proteins: homology to an extracellular matrix receptor defines a novel supergene family. Cell (1987) 4.70
Relation of fetal and infant growth to plasma fibrinogen and factor VII concentrations in adult life. BMJ (1992) 4.53
A group of interacting yeast DNA replication genes. Genes Dev (1991) 4.45
Assessing effectiveness of treatment of depression in primary care. Partially randomised preference trial. Br J Psychiatry (2000) 4.44
Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob Agents Chemother (1992) 4.43
Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med (2000) 4.36
Health-related quality of life in patients served by the Department of Veterans Affairs: results from the Veterans Health Study. Arch Intern Med (1998) 4.07
Development of the Drosophila mushroom bodies: sequential generation of three distinct types of neurons from a neuroblast. Development (1999) 3.96
High-density SNP analysis of 642 Caucasian families with rheumatoid arthritis identifies two new linkage regions on 11p12 and 2q33. Genes Immun (2006) 3.86
Antidepressant drugs and generic counselling for treatment of major depression in primary care: randomised trial with patient preference arms. BMJ (2001) 3.81
Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci U S A (1991) 3.76
Kinetic interactions of tazobactam with beta-lactamases from all major structural classes. Antimicrob Agents Chemother (1993) 3.74
Campylobacter pyloridis gastritis I: Detection of urease as a marker of bacterial colonization and gastritis. Am J Gastroenterol (1987) 3.65
Structural conservation in prokaryotic and eukaryotic potassium channels. Science (1998) 3.61
Phylogeny of Helicobacter felis sp. nov., Helicobacter mustelae, and related bacteria. Int J Syst Bacteriol (1991) 3.46
Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J Clin Invest (2001) 3.41
Laryngotracheal stenosis: a serious complication of percutaneous tracheostomy. Anaesthesia (1994) 3.36
Endotoxin-induced maturation of MyD88-deficient dendritic cells. J Immunol (2001) 3.26
Campylobacter pyloridis, urease, hydrogen ion back diffusion, and gastric ulcers. Lancet (1986) 3.24
Crystal structure and functional analysis of the HERG potassium channel N terminus: a eukaryotic PAS domain. Cell (1998) 3.22
In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines. Antimicrob Agents Chemother (1993) 3.13
Sialic acid species as a determinant of the host range of influenza A viruses. J Virol (2000) 3.10
Specificity and promiscuity in phosphoinositide binding by pleckstrin homology domains. J Biol Chem (1998) 3.07
Independent mechanisms involved in suppression of the Moloney leukemia virus genome during differentiation of murine teratocarcinoma cells. Cell (1983) 3.06
The microbial ecology of the large bowel of breast-fed and formula-fed infants during the first year of life. J Med Microbiol (1982) 3.04
Mucus colonization as a determinant of pathogenicity in intestinal infection by Campylobacter jejuni: a mouse cecal model. Infect Immun (1986) 3.03
A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat Genet (1996) 2.98
Addition of physicians to paramedic helicopter services decreases blunt trauma mortality. Aust N Z J Surg (1999) 2.89
Arabidopsis COP8, COP10, and COP11 genes are involved in repression of photomorphogenic development in darkness. Plant Cell (1994) 2.89
Specificity of antibodies to immunodominant mycobacterial antigens in pulmonary tuberculosis. J Clin Microbiol (1988) 2.79
The chromosome end in yeast: its mosaic nature and influence on recombinational dynamics. Genetics (1994) 2.70
A body image scale for use with cancer patients. Eur J Cancer (2001) 2.68
Frequency of a 22q11 deletion in patients with conotruncal cardiac malformations: a prospective study. Eur J Pediatr (1995) 2.66
Helicobacter mustelae-associated gastritis in ferrets. An animal model of Helicobacter pylori gastritis in humans. Gastroenterology (1990) 2.64
Epidemiology of Helicobacter pylori in southern China: identification of early childhood as the critical period for acquisition. J Infect Dis (1992) 2.60
Prospective evaluation of patients refused admission to an intensive care unit: triage, futility and outcome. Intensive Care Med (2001) 2.59
An uncultured gastric spiral organism is a newly identified Helicobacter in humans. J Infect Dis (1993) 2.53
Mutations in exons 2 and 3 of the cationic trypsinogen gene in Japanese families with hereditary pancreatitis. Gut (1999) 2.51
Biological properties of interleukin 10. J Clin Immunol (1992) 2.50
Acute toxicity of ropivacaine compared with that of bupivacaine. Anesth Analg (1989) 2.49
The mouse intestinal microflora with emphasis on the strict anaerobes. J Exp Med (1971) 2.46
Transcriptional activation of Salmonella typhimurium invasion genes by a member of the phosphorylated response-regulator superfamily. Mol Microbiol (1996) 2.46
A whole blood immunoassay using gold nanoshells. Anal Chem (2003) 2.45
Diagnosis of major chromosome aneuploidies in human preimplantation embryos. Hum Reprod (1993) 2.45
Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene. Antimicrob Agents Chemother (1996) 2.42
Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance. J Bacteriol (2000) 2.41
IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc Natl Acad Sci U S A (1999) 2.35
Health status in VA patients: results from the Veterans Health Study. Am J Med Qual (1999) 2.35
Essential roles of Drosophila RhoA in the regulation of neuroblast proliferation and dendritic but not axonal morphogenesis. Neuron (2000) 2.31
GSP1 and GSP2, genetic suppressors of the prp20-1 mutant in Saccharomyces cerevisiae: GTP-binding proteins involved in the maintenance of nuclear organization. Mol Cell Biol (1993) 2.30
The urease enzymes of Campylobacter pylori and a related bacterium. J Med Microbiol (1988) 2.25
Helicobacter pylori infection in children: potential clues to pathogenesis. J Pediatr Gastroenterol Nutr (1993) 2.25
Randomised controlled trial of computer assisted management of hypertension in primary care. Br Med J (Clin Res Ed) (1986) 2.24
Cloning of a type I TGF-beta receptor and its effect on TGF-beta binding to the type II receptor. Science (1993) 2.20
Peripherally inserted central catheter-related deep vein thrombosis: contemporary patterns and predictors. J Thromb Haemost (2014) 2.18
Differentiation of subtypes within Leptospira interrogans serovars Hardjo, Balcanica and Tarassovi, by bacterial restriction-endonuclease DNA analysis (BRENDA). J Med Microbiol (1982) 2.17
Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med (2000) 2.16
A new type of transforming growth factor-beta, TGF-beta 3. EMBO J (1988) 2.12
Atypical presentations of pityriasis rosea: case presentations. J Eur Acad Dermatol Venereol (2005) 2.11
Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin. J Med Chem (1999) 2.10
Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A (1997) 2.10
Campylobacter pylori, duodenal ulcer, and gastric metaplasia: possible role of functional heterotopic tissue in ulcerogenesis. Gut (1989) 2.06
Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis (1997) 2.06
Impact of siderophore production on Pseudomonas aeruginosa infections in immunosuppressed mice. Infect Immun (2000) 2.05
Cellular responses to bacterial cell wall components are mediated through MyD88-dependent signaling cascades. Int Immunol (2000) 2.05
Systems and strategies for managing the drugs budget in Glasgow. BMJ (1998) 2.01
Global analysis of Escherichia coli gene expression during the acetate-induced acid tolerance response. J Bacteriol (2001) 1.99
Campylobacter pyloridis gastritis II: Distribution of bacteria and associated inflammation in the gastroduodenal environment. Am J Gastroenterol (1987) 1.98
Purification and characterization of three inhibitors of voltage-dependent K+ channels from Leiurus quinquestriatus var. hebraeus venom. Biochemistry (1994) 1.97
Involvement of pp60c-src with two major signaling pathways in human breast cancer. Proc Natl Acad Sci U S A (1994) 1.94
Person-to-person transmission of Campylobacter pylori. Lancet (1987) 1.93
Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines. J Med Chem (1994) 1.93
Bone atrophy in complex regional pain syndrome patients measured by microdensitometry. Can J Anaesth (1998) 1.93
Localization of bacteria in the gastrointestinal tract: a possible explanation of intestinal spirochaetosis. Infect Immun (1973) 1.92
Isolation and characterization of a spiral bacterium from the crypts of rodent gastrointestinal tracts. Appl Environ Microbiol (1983) 1.91
Local and systemic immune responses in murine Helicobacter felis active chronic gastritis. Infect Immun (1993) 1.90
Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure. Lancet (1999) 1.89
Comparative analysis of multiple-casualty incident triage algorithms. Ann Emerg Med (2001) 1.89
Helicobacter pylori gastric infection in gnotobiotic beagle dogs. Infect Immun (1990) 1.88